Holen Sie sich die Stockscreener-App
27.84
6.12%
1.95
Handel nachbörslich:
27.84
Hemab Therapeutics Holdings Inc Aktie (COAG) Neueste Nachrichten
Hemab Therapeutics (COAG) Earnings Date and Reports 2026 - MarketBeat
Hemab Therapeutics Hldgs Initiated at Buy by Jefferies - Moomoo
COAG Initiates Coverage By Evercore ISI Group -- Rating Upgraded to Outperform - GuruFocus
This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Goldman Sachs Initiates Coverage on Hemab Therapeutics With Buy Rating, $36 Price Target - marketscreener.com
Goldman Sachs Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $36 - Moomoo
Goldman Sachs initiates Hemab Therapeutics stock with buy rating on rare disease drug potential - Investing.com Australia
ETFs Investing in Hemab Therapeutics Holdings, Inc. Stocks - TradingView
Top Hemab Therapeutics (COAG) Competitors 2026 - MarketBeat
COAG Technical Analysis | Trend, Signals & Chart Patterns | HEMAB THERAPEUTICS HOLDINGS (NASDAQ:COAG) - ChartMill
Earnings Scheduled For May 21, 2026 - Sahm
Novo-backed biotech Hemab raises $301.5 million in upsized IPO - MSN
COAG SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Hemab Therapeutics Holdings, Inc. Q1 2026: Net loss $(22.7)M, EPS $(23.98) — 10-Q Summary - TradingView
Hemab Therapeutics Reports Q1 2026 Financial Results, Completes $346.7M IPO and Advances Breakthrough Therapy Sutacimig for Rare Bleeding Disorders - Minichart
Earnings Flash (COAG) Hemab Therapeutics Posts Q1 Net Loss $23.98 a Share - marketscreener.com
Hemab Therapeutics reports Q1 2026 net loss $22.7M, cash $163.5M; completed $346.7M IPO - TradingView
COAG: IPO raised $346.7M, advancing late-stage trials for rare bleeding disorder therapies - TradingView
Hemab Therapeutics (COAG) Q1 2026 loss, $346.7M IPO and FDA breakthrough nod - Stock Titan
FDA grants Hemab breakthrough tag on rare bleed drug as $346.7M IPO closes - Stock Titan
Hemab Therapeutics (COAG) 10K Form and Latest SEC Filings 2026 - MarketBeat
Hemab Therapeutics (COAG) Stock Forecast and Price Target 2026 - MarketBeat
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) AI-Powered Stock Analysis - Meyka
Hemab Therapeutics Hldgs (COAG) Stock Analysis Report | Financials & Insights - Benzinga España
Why Is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock Up Today? - Meyka
Why Is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock Down Today? - Meyka
Seaport, Hemab price upsized IPOs, eyeing $550M in proceeds - MSN
COAG SEC FilingsHEMAB THERAPEUTICS HOLDINGS 10-K, 10-Q, 8-K Forms - Stock Titan
Hemab Therapeutics Holdings Earnings Date, Reports & Earnings Call - Moomoo
Hemab Therapeutics Holdings (COAG) Stock Forecast & Analyst Ratings - Moomoo
Hemab Therapeutics Holdings Inc. (COAG) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Hemab, Seaport surge as clinical-stage biotechs make trading debuts - MSN
AI DEN-MAB LLC discloses 4,876,344 Hemab Therapeutics (COAG) shares - Stock Titan
Hemab Therapeutics (COAG) Stock Trends and Sentiment 2026 - MarketBeat
Hemab Therapeutics Closes Upsized Initial Public Offering on Nasdaq - Global Legal Chronicle
RA Capital reveals 16.6% stake in Hemab Therapeutics (NASDAQ: COAG) - Stock Titan
RA Capital funds boost Hemab Therapeutics (COAG) stake with open-market buys - Stock Titan
Hemab Therapeutics (COAG) Insider Trading Activity 2026 - MarketBeat
Access Industries (NASDAQ: COAG) discloses 10.4% Hemab Therapeutics ownership stake - Stock Titan
Board member Laura Tadvalkar resigns from Hemab Therapeutics (NASDAQ: COAG) board - Stock Titan
Hemab Therapeutics Holdings, Inc. Announces Resignation of Laura Tadvalkar as Member of the Board of Directors , Effective on May 8, 2026 - marketscreener.com
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):